Teva Pharmaceutical Industries Limited (TEV) — Capital Reinvestment Ratio

Latest as of December 2025: 0.12x

Teva Pharmaceutical Industries Limited (TEV) has a Capital Reinvestment Ratio of 0.12x as of December 2025, meaning it reinvests 0% of its operating cash flow (€1.16 Billion) in capital expenditures (€142.00 Million). See TEV equity financing ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.12x
Capex / Operating Cash Flow

Operating Cash Flow

€1.16 Billion
EUR

Capital Expenditures

€142.00 Million
EUR

Data as of

Dec 2025
Most recent filing

Teva Pharmaceutical Industries Limited Capital Reinvestment Ratio (2015–2025)

This chart tracks Teva Pharmaceutical Industries Limited's Capital Reinvestment Ratio across 11 annual periods. Check Teva Pharmaceutical Industries Limited cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Teva Pharmaceutical Industries Limited (2015–2025)

Year-by-year Capital Reinvestment Ratio for Teva Pharmaceutical Industries Limited from 2015 to 2025. For live market cap and broader valuation context, see Teva Pharmaceutical Industries Limited stock valuation.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2025 0.30x €1.65 Billion €501.00 Million ▼ -23.9%
2024 0.40x €1.25 Billion €498.00 Million ▼ -15.8%
2023 0.47x €1.16 Billion €549.00 Million ▲ +37.7%
2022 0.34x €1.59 Billion €548.00 Million ▼ -51.1%
2021 0.70x €798.00 Million €562.00 Million ▲ +48.2%
2020 0.48x €1.22 Billion €578.00 Million ▼ -32.3%
2019 0.70x €748.00 Million €525.00 Million ▲ +163.7%
2018 0.27x €2.45 Billion €651.00 Million ▼ -32.2%
2017 0.39x €2.23 Billion €874.00 Million ▲ +69.6%
2016 0.23x €3.89 Billion €901.00 Million ▲ +66.3%
2015 0.14x €5.54 Billion €772.00 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow